Skip to content

Menu

LexBlog, Inc. logo
CommunitySub-MenuPublishersChannelsProductsSub-MenuBlog ProBlog PlusBlog PremierMicrositeSyndication PortalsAboutContactResourcesSubscribeSupport
Join
Search
Close

Updated EMA guidance on centrally authorised medicines raises new considerations for Brexit preparations

By Elisabethann Wright, Jane Summerfield, Marta Miglietti & Julia Fraser on June 29, 2018
Email this postTweet this postLike this postShare this post on LinkedIn

On 19 June 2018, the European Medicines Agency (EMA) published updates to its Brexit Q&A document for human and veterinary medicines authorised via the centralised procedure and to its practical procedural guidance on making Brexit related changes to the authorisations for those products.

The updated version (“Rev 03”) of the EMA Q&A document includes new paragraphs relating to the validity of inspections carried out by UK inspectors, multi-country packaging, back-up arrangements for pharmacovigilance, batch release certificates for human immunological and human blood and plasma medicinal products, and the procedure for assessment of ancillary medicinal substances.

In particular, the new information confirms:

  • the outcome of inspections carried out by the UK competent authority (the MHRA) before 30 March 2019 relating to good manufacturing practice, good clinical practice and pharmacovigilance obligations will continued to be recognised following Brexit;
  • it will only be possible to include UK labelling information on packaging for medicinal products intended for multiple EU markets if the UK information is fully compatible the summary of product characteristics as authorised in the EU;
  • back-up arrangements for situations in which the Qualified Person for Pharmacovigilance is absent will need to be transferred to another EU Member State if they are currently based in the UK;
  • human immunological medicinal products and medicinal products derived from human blood or plasma that have been tested and certified for batch release by an Official Medicines Control Laboratory (OMCL) or by a designated laboratory located in the UK will no longer be permitted to be placed on the EU market following Brexit. Marketing authorisation holders (MAHs) will need to appoint an OMCL located in the EEA or batch release will need to be carried out by a country with which the EU has a mutual recognition agreement; and
  • manufacturers of medical devices which incorporate ancillary medicinal substances will no longer be able to appoint a UK notified body for the purposes of obtaining a scientific opinion from the EMA or a competent national authority concerning the quality and safety of the ancillary medicine.

The updates to the procedural document include new guidance on:

  • changing a UK based applicant for an on-going marketing authorisation application to an applicant established in another EU Member State;
  • how the assignment of existing rapporteurs and co-rapporteurs from the UK to another EU member state will work in practice. This procedural guidance follows the redistribution of the UK’s portfolio of centrally authorised medicinal products and the reallocation of UK rapporteurs and co-rapporteurs, which has been agreed by the EMA and the national competent authorities in April 2018 (link);
  • timings for submitting Brexit-related type IA variations;
  • combining multiple transfers of orphan designations from the UK to another EU Member State; and
  • considerations when changing the pharmacovigilance system master file (PSMF) location from the UK to a remaining EU Member State.

The Q&A and procedural guidance supplement the EMA’s Notice to holders of centrally authorised marketing authorisations, last updated in January 2018. The Notice emphasises the need for MAHs to ensure the continuity of supply of medicines in the EU following Brexit and proactively review the marketing authorisations they hold to assess the need for any changes.

Both documents are based on the UK leaving the EU on 29 March 2019 without any transitional arrangements in place.

Photo of Elisabethann Wright Elisabethann Wright
Read more about Elisabethann WrightEmail
Photo of Jane Summerfield Jane Summerfield

Partner, London

Jane focuses on regulatory compliance and commercial agreements in the life sciences and food sectors. Jane advises on legal and regulatory requirements that apply during the product lifecycle, including clinical trial requirements, early access schemes, marketing authorisations, manufacturing and distribution licences…

Partner, London

Jane focuses on regulatory compliance and commercial agreements in the life sciences and food sectors. Jane advises on legal and regulatory requirements that apply during the product lifecycle, including clinical trial requirements, early access schemes, marketing authorisations, manufacturing and distribution licences, CE marking, product labelling, product composition, advertising and marketing activities, and pricing and reimbursement. Jane also advises on a wide range of commercial contractual arrangements, including consultancy, sponsorship, co-promotion, collaboration, manufacturing, distribution, services, quality and pharmacovigilance agreements, as well as helping clients to resolve issues with UK enforcement authorities and regulatory bodies, such as the Medicines and Healthcare products Regulatory Agency (MHRA), Prescription Medicines Code of Practice Authority (PMCPA), Advertising Standards Authority (ASA), Food Standards Agency (FSA) and Trading Standards.
Jane combines commercial acumen with deep regulatory knowledge. She understands the business pressures faced by clients, having provided in-house regulatory compliance and commercial support to a major pharmaceutical client and a multinational food company. Jane provides “clear responses with business impact” Chambers UK.

Read more about Jane SummerfieldEmail
Show more Show less
  • Posted in:
    Administrative
  • Blog:
    Focus on Regulation
  • Organization:
    Hogan Lovells
  • Article: View Original Source

LexBlog, Inc. logo
Facebook LinkedIn Twitter RSS
Real Lawyers
99 Park Row
  • About LexBlog
  • Careers
  • Press
  • Contact LexBlog
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Terms of Service
  • RSS Terms of Service
  • Products
  • Blog Pro
  • Blog Plus
  • Blog Premier
  • Microsite
  • Syndication Portals
  • LexBlog Community
  • 1-800-913-0988
  • Submit a Request
  • Support Center
  • System Status
  • Resource Center

New to the Network

  • The FTI Award Journal
  • International Dispute Resolution
  • China Law Update Blog
  • Law of The Ledger
  • Antitrust Law Blog
Copyright © 2022, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo